GCG, glucagon, 2641

N. diseases: 441; N. variants: 10
Disease: Short Bowel Syndrome ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0036992
Disease: Short Bowel Syndrome
Short Bowel Syndrome 		0.100 Biomarker disease BEFREE <b>NEW & NOTEWORTHY</b> Therapeutic activation of endogenous glucagon-like peptide 2 (GLP-2) secretion is a promising strategy to improve intestinal adaptation in patients with short bowel syndrome. 30920308 2019
CUI: C0036992
Disease: Short Bowel Syndrome
Short Bowel Syndrome 		0.100 Biomarker disease BEFREE GLP-1 and GLP-2 are gut-derived hormones used in the treatment of diabetes type-2 and short bowel syndrome, respectively. 28266749 2019
CUI: C0036992
Disease: Short Bowel Syndrome
Short Bowel Syndrome 		0.100 Biomarker disease BEFREE Novel effect of glucagon-like peptide-2 for hepatocellular injury in a parenterally fed rat model of short bowel syndrome. 31555865 2019
CUI: C0036992
Disease: Short Bowel Syndrome
Short Bowel Syndrome 		0.100 Biomarker disease BEFREE GLP-2 analogues are emerging as an important treatment for patients with short bowel syndrome. 30111847 2019
CUI: C0036992
Disease: Short Bowel Syndrome
Short Bowel Syndrome 		0.100 Biomarker disease BEFREE With the introduction of glucagon-like peptide-2 (GLP-2) in the treatment of short bowel syndrome (SBS), there is emerging evidence that GLP-2 may play a role in the restoration of the disturbed homeostatic feedback in the gut-liver axis and may ameliorate SBS-associated liver damage. 31326433 2019
CUI: C0036992
Disease: Short Bowel Syndrome
Short Bowel Syndrome 		0.100 Biomarker disease BEFREE Exogenous GLP-2 is currently available as teduglutide for the treatment of short bowel syndrome. 29741675 2018
CUI: C0036992
Disease: Short Bowel Syndrome
Short Bowel Syndrome 		0.100 Biomarker disease BEFREE Short bowel syndrome: influence of nutritional therapy and incretin GLP1 on bone marrow adipose tissue. 29509291 2018
CUI: C0036992
Disease: Short Bowel Syndrome
Short Bowel Syndrome 		0.100 Biomarker disease BEFREE Teduglutide is an analog of glucagon-like peptide 2 (GLP-2) which is approved for the treatment of patients with short bowel syndrome (SBS) who are dependent on parenteral support. 29848084 2018
CUI: C0036992
Disease: Short Bowel Syndrome
Short Bowel Syndrome 		0.100 Biomarker disease BEFREE Due to these effects GLP-2 is used in the treatment of short bowel syndrome (SBS). 29231791 2018
CUI: C0036992
Disease: Short Bowel Syndrome
Short Bowel Syndrome 		0.100 Biomarker disease BEFREE Teduglutide is a GLP-2 analogue indicated for treatment of adults with short bowel syndrome (SBS). 27433811 2017
CUI: C0036992
Disease: Short Bowel Syndrome
Short Bowel Syndrome 		0.100 Biomarker disease BEFREE The discovery that GLP-2 promotes mucosal growth in the intestine is described, and key findings from both preclinical studies and the GLP-2 clinical development program for short bowel syndrome (SBS) are reviewed. 29202475 2017
CUI: C0036992
Disease: Short Bowel Syndrome
Short Bowel Syndrome 		0.100 Biomarker disease BEFREE Glucagon-like peptide-2 (GLP-2) affects multiple facets of gastrointestinal physiology and have been used to treat patients with short bowel syndrome, but the distribution of its receptor (GLP2R) in human remains poorly understood. 28337026 2017
CUI: C0036992
Disease: Short Bowel Syndrome
Short Bowel Syndrome 		0.100 Biomarker disease BEFREE Teduglutide is an enterotrophic analog of glucagon-like peptide 2 approved for the rehabilitation of short-bowel syndrome. 28807218 2017
CUI: C0036992
Disease: Short Bowel Syndrome
Short Bowel Syndrome 		0.100 Biomarker disease BEFREE GLP-2 is a gut hormone known to be trophic for small bowel mucosa, and to mimic intestinal adaptation in short bowel syndrome (SBS). 28738080 2017
CUI: C0036992
Disease: Short Bowel Syndrome
Short Bowel Syndrome 		0.100 Biomarker disease BEFREE To determine whether these growth factors exert synergistic effects on intestinal growth and function, GLP-2 and EGF-containing media (EGF-cm) were administered, alone and in combination, in neonatal piglet models of short bowel syndrome (SBS). 28104586 2017
CUI: C0036992
Disease: Short Bowel Syndrome
Short Bowel Syndrome 		0.100 Biomarker disease BEFREE GLP-2, despite its known trophic and anti-inflammatory intestinal actions translated into preliminary clinical studies using the GLP-2 analogue teduglutide for treatment of short bowel syndrome and Crohn's disease, remains poorly characterized in terms of expression of its receptor in tissues of interest. 22951144 2012
CUI: C0036992
Disease: Short Bowel Syndrome
Short Bowel Syndrome 		0.100 Biomarker disease LHGDN In this review, the nature of short-bowel syndrome is described and the antisecretory, transit modulating and intestinotrophic effects of GLP-2 are presented. 14608103 2003